• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

透析患者与肾移植患者生存率的比较分析。

A comparative analysis of survival of patients on dialysis and after kidney transplantation.

作者信息

Kaballo Mohammed A, Canney Mark, O'Kelly Patrick, Williams Yvonne, O'Seaghdha Conall M, Conlon Peter J

机构信息

Department of Nephrology and Transplantation, Beaumont Hospital, Dublin, Ireland.

出版信息

Clin Kidney J. 2018 Jun;11(3):389-393. doi: 10.1093/ckj/sfx117. Epub 2017 Oct 18.

DOI:10.1093/ckj/sfx117
PMID:29942504
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6007575/
Abstract

BACKGROUND

Kidney transplant survival benefits are not observed for around 8 months after transplantation because of a higher complications rate in early post-transplant periods. This study compares survival of patients awaiting transplantation with survival of transplant recipients and non-listed dialysis patients in Ireland.

METHODS

In this retrospective analysis, the relative-risk (RR) of death was assessed with time-dependent, non-proportional hazards analysis, with adjustment for age, cause of end-stage kidney disease (ESKD), time from first treatment for ESKD to placement on the waiting list and year of initial placement on the list.

RESULTS

A total of 3597 patients were included. Annual death rates per 100 patient-years at risk for all patients on dialysis, waiting-list patients and transplant recipients were 16.5, 2.4 and 1.2, respectively. Death rate was highest among diabetics. The relative risk of death for all patients on dialysis was five times higher than the waiting-list patients [RR, 4.90; 95% confidence interval (CI), 3.70-6.52; P < 0.001]. Time to survival equilibration was 1 year. Thereafter, the 5-year mortality risk was estimated to be 47% lower than that of the patients on the waiting list (RR, 0.53; 95% CI, 0.37-0.77; P = 0.001).

CONCLUSIONS

Transplant recipients had a higher risk of death initially, but a better long-term survival. Time to death risk equilibration was longer compared with other studies. This could be explained by better survival rates in our waiting-list cohort.

摘要

背景

由于移植后早期并发症发生率较高,肾移植患者在移植后约8个月内未观察到生存获益。本研究比较了爱尔兰等待移植患者、移植受者和未列入名单的透析患者的生存率。

方法

在这项回顾性分析中,采用时间依赖性非比例风险分析评估死亡相对风险,并对年龄、终末期肾病(ESKD)病因、从首次治疗ESKD到列入等待名单的时间以及首次列入名单的年份进行调整。

结果

共纳入3597例患者。所有透析患者、等待名单患者和移植受者每100患者年的年死亡率分别为16.5、2.4和1.2。糖尿病患者的死亡率最高。所有透析患者的死亡相对风险比等待名单患者高五倍[相对风险(RR),4.90;95%置信区间(CI),3.70 - 6.52;P < 0.001]。生存平衡时间为1年。此后,估计5年死亡风险比等待名单上的患者低47%(RR,0.53;95% CI,0.37 - 0.77;P = 0.001)。

结论

移植受者最初死亡风险较高,但长期生存率较好。与其他研究相比,死亡风险平衡时间更长。这可能是由于我们等待名单队列中的生存率更高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dc/6007575/a52352762c6d/sfx117f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dc/6007575/d468581a8372/sfx117f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dc/6007575/a52352762c6d/sfx117f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dc/6007575/d468581a8372/sfx117f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dc/6007575/a52352762c6d/sfx117f2.jpg

相似文献

1
A comparative analysis of survival of patients on dialysis and after kidney transplantation.透析患者与肾移植患者生存率的比较分析。
Clin Kidney J. 2018 Jun;11(3):389-393. doi: 10.1093/ckj/sfx117. Epub 2017 Oct 18.
2
Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.透析患者、等待移植的透析患者以及首次尸体器官移植受者的死亡率比较。
N Engl J Med. 1999 Dec 2;341(23):1725-30. doi: 10.1056/NEJM199912023412303.
3
Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada.加拿大安大略省透析患者与尸体供肾首次肾移植受者死亡风险的比较。
J Am Soc Nephrol. 2000 May;11(5):917-922. doi: 10.1681/ASN.V115917.
4
Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients.终末期肾病患者的生存改善情况:移植受者和等待名单上患者随时间的趋势
J Am Soc Nephrol. 2001 Jun;12(6):1293-1296. doi: 10.1681/ASN.V1261293.
5
Survival of recipients of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand, 1991-2001.1991 - 2001年澳大利亚和新西兰尸体肾移植受者与接受透析治疗者的生存率比较
Nephrol Dial Transplant. 2002 Dec;17(12):2212-9. doi: 10.1093/ndt/17.12.2212.
6
Deceased-donor characteristics and the survival benefit of kidney transplantation.已故供体特征与肾移植的生存获益
JAMA. 2005 Dec 7;294(21):2726-33. doi: 10.1001/jama.294.21.2726.
7
Survival of patients with kidney failure awaiting transplantation stratified by age and ethnicity: population-based cohort analysis.按年龄和种族分层的肾衰竭等待移植患者的生存率:基于人群的队列分析。
Br J Surg. 2024 Jan 3;111(1). doi: 10.1093/bjs/znae001.
8
Outcomes of renal transplant and waiting list patients with bacterial endocarditis in the United States.美国肾移植患者及等待名单上的患者患细菌性心内膜炎的结局。
Nephrol Dial Transplant. 2008 Jul;23(7):2381-5. doi: 10.1093/ndt/gfn006. Epub 2008 Feb 26.
9
Left ventricular assist devices: an evidence-based analysis.左心室辅助装置:基于证据的分析
Ont Health Technol Assess Ser. 2004;4(3):1-69. Epub 2004 Mar 1.
10
Association between kidney transplant center performance and the survival benefit of transplantation versus dialysis.肾移植中心的表现与移植相对于透析的生存获益之间的关联。
Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1773-80. doi: 10.2215/CJN.02380314. Epub 2014 Sep 18.

引用本文的文献

1
Diabetes Mellitus in Kidney Transplant Recipients and New Hypoglycemic Agent Options.肾移植受者中的糖尿病及新型降糖药物选择
Int J Mol Sci. 2025 Jun 20;26(13):5952. doi: 10.3390/ijms26135952.
2
Factors Influencing the Information Support Provided by Health Care Professionals to Patients in a Dialysis Center Regarding Kidney Transplantation: A Nationwide Study.影响透析中心医护人员向患者提供的关于肾移植的信息支持的因素:一项全国性研究
Transpl Int. 2025 May 14;38:14159. doi: 10.3389/ti.2025.14159. eCollection 2025.
3
Outcomes of pancreas transplantation over two decades: a single-center retrospective cohort study.

本文引用的文献

1
OPTN/SRTR 2013 Annual Data Report: kidney.OPTN/SRTR 2013 年度数据报告:肾脏。
Am J Transplant. 2015 Jan;15 Suppl 2:1-34. doi: 10.1111/ajt.13195.
2
Quantification of the early risk of death in elderly kidney transplant recipients.老年肾移植受者早期死亡风险的量化。
Am J Transplant. 2013 Feb;13(2):427-32. doi: 10.1111/j.1600-6143.2012.04323.x. Epub 2012 Nov 21.
3
Access to kidney transplantation among the elderly in the United States: a glass half full, not half empty.美国老年人的肾移植机会:半满的玻璃杯,而非半空的。
二十年胰腺移植的结果:一项单中心回顾性队列研究。
Ann Surg Treat Res. 2025 May;108(5):271-278. doi: 10.4174/astr.2025.108.5.271. Epub 2025 Apr 28.
4
spp. Infection in Kidney Transplant Recipient.肾移植受者中的特定种感染。
Pathogens. 2025 Apr 1;14(4):341. doi: 10.3390/pathogens14040341.
5
Access to Transplant for African American and Latino Patients Under the 2014 US Kidney Allocation System.2014年美国肾脏分配系统下非裔美国人和拉丁裔患者的移植机会
Transplantation. 2025 Aug 1;109(8):1413-1424. doi: 10.1097/TP.0000000000005360. Epub 2025 Mar 11.
6
Identification of urinary metabolites correlated with tacrolimus levels through high-precision liquid chromatography-mass spectrometry and machine learning algorithms in kidney transplant patients.通过高精度液相色谱-质谱联用技术和机器学习算法鉴定肾移植患者中与他克莫司水平相关的尿液代谢物。
Med Pharm Rep. 2025 Jan;98(1):125-134. doi: 10.15386/mpr-2805. Epub 2025 Jan 31.
7
Evaluation of efficacy and safety of generic tacrolimus (Suprotac) compared to reference tacrolimus (Prograf) in kidney transplantation: a phase IV study.肾移植中与参比他克莫司(普乐可复)相比,仿制药他克莫司(舒普深)的疗效和安全性评估:一项IV期研究。
Eur J Transl Myol. 2025 Mar 31;35(1). doi: 10.4081/ejtm.2025.13203. Epub 2025 Jan 21.
8
Epidemiological profile of kidney transplant patients with lupus nephritis.狼疮性肾炎肾移植患者的流行病学概况。
J Bras Nefrol. 2025 Apr-Jun;47(2):e20240061. doi: 10.1590/2175-8239-JBN-2024-0061en.
9
Risk factors for SARS-CoV-2 pneumonia among renal transplant recipients in Omicron pandemic-a prospective cohort study.奥密克戎大流行期间肾移植受者感染新型冠状病毒肺炎的危险因素——一项前瞻性队列研究
Virol J. 2024 Dec 4;21(1):315. doi: 10.1186/s12985-024-02591-9.
10
Late Recurrence of C3 Glomerulopathy After SARS-CoV-2 Infection in a Long-Term Kidney Transplant Recipient: A Case Report.一名长期肾移植受者感染新型冠状病毒后C3肾小球病的迟发性复发:病例报告
Am J Case Rep. 2024 Dec 4;25:e944208. doi: 10.12659/AJCR.944208.
Clin J Am Soc Nephrol. 2010 Nov;5(11):2109-14. doi: 10.2215/CJN.03490410. Epub 2010 Oct 28.
4
Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies.潜在肾移植候选人的心血管风险评估:方法与争议。
Am J Kidney Dis. 2010 Jan;55(1):152-67. doi: 10.1053/j.ajkd.2009.06.032. Epub 2009 Sep 23.
5
Half of kidney transplant candidates who are older than 60 years now placed on the waiting list will die before receiving a deceased-donor transplant.目前被列入等待名单的60岁以上的肾移植候选者中,有一半会在接受尸体供体移植前死亡。
Clin J Am Soc Nephrol. 2009 Jul;4(7):1239-45. doi: 10.2215/CJN.01280209. Epub 2009 Jun 18.
6
The importance of transitions between dialysis and transplantation in the care of end-stage renal disease patients.透析与移植之间的过渡在终末期肾病患者护理中的重要性。
Kidney Int. 2007 Mar;71(5):442-7. doi: 10.1038/sj.ki.5002072. Epub 2007 Jan 17.
7
Deceased-donor characteristics and the survival benefit of kidney transplantation.已故供体特征与肾移植的生存获益
JAMA. 2005 Dec 7;294(21):2726-33. doi: 10.1001/jama.294.21.2726.
8
The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation.等待时间和合并症对肾移植生存获益的影响。
Kidney Int. 2005 Nov;68(5):2345-51. doi: 10.1111/j.1523-1755.2005.00696.x.
9
Death in the first year after kidney transplantation: implications for patients on the transplant waiting list.肾移植后第一年的死亡情况:对移植等待名单上患者的影响
Transplantation. 2003 Jan 15;75(1):113-7. doi: 10.1097/00007890-200301150-00021.
10
Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.透析患者、等待移植的透析患者以及首次尸体器官移植受者的死亡率比较。
N Engl J Med. 1999 Dec 2;341(23):1725-30. doi: 10.1056/NEJM199912023412303.